Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.
Marketing Status Prescription; Discontinued
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 50268-063; 49711-0113; 16714-041; 0603-2116; 14445-001; 69967-008; 55700-879; 50090-4662; 23155-694; 53489-156; 0591-5544; 0904-7041; 0378-0181; 55700-935; 66267-665; 61919-748; 50090-5194; 67457-187; 51079-206; 63739-796; 43063-976; 68083-380; 23155-693; 70518-1678; 71335-0112; 17351-0041; 55700-540; 67296-1265; 71610-253; 63629-2113; 51079-205; 50268-064; 29300-350; 68071-2660; 70934-072; 55700-947; 55154-5534; 50090-0044; 70934-389; 61919-471; 55111-730; 68071-1805; 71610-197; 70518-3289; 70710-1210; 63629-1781; 58118-1156; 67296-1314; 49452-0008; 70518-1806; 65015-606; 16729-135; 0904-6571; 63552-151; 70771-1127; 55154-2338; 62584-988; 70199-016; 70710-1209; 43353-088; 55154-7892; 16729-134; 0615-8385; 0591-5543; 68108-0212; 71205-208; 63629-8020; 43063-975; 71335-0467; 70771-1126; 68071-2616; 63187-240; 53002-4821; 36974-0018; 50090-2544; 69967-009; 70934-504; 63629-7908; 0615-8321; 51927-0070; 71610-064; 63629-2111; 50090-5168; 71610-194; 60760-134; 53002-4820; 65219-380; 70934-295; 65977-0124; 43063-793; 70199-015; 67457-978; 71610-231; 67544-736; 50090-3760; 43063-079; 71205-377; 62584-713; 71205-049; 50090-4663; 63629-1675; 63552-150; 0378-0137; 16714-042; 16714-577; 55154-7981; 16714-576; 43063-935; 29300-349; 70934-209; 70518-0451; 55289-010; 43353-186; 0603-2115; 55154-5454; 43063-774; 71335-1656; 55111-729; 60760-139; 0904-6572; 63629-2112; 70934-681; 43063-934; 50090-3758; 63739-410; 57451-1166; 60429-180; 66064-2100; 51927-1915; 66267-224; 68788-7542; 53489-157; 63187-463; 70518-1573; 68788-7383
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Aplasia pure red cellGlycophorin-AP02724Not Available10398315; 16076905; 11816258
Reperfusion injuryIntercellular adhesion molecule 1P05362T2620314614706; 9583490; 9744646
Reperfusion injuryMyeloperoxidaseP05164T2347114614706; 9583490; 9744646
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Exfoliative rash23.03.07.0060.000052%Not Available
Oral mucosa erosion07.05.06.0090.000132%Not Available
Chronic kidney disease20.01.03.0170.000923%
Ulcerative keratitis10.02.01.021; 06.04.02.0040.000155%
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.000198%Not Available
Meibomian gland dysfunction06.04.04.0150.000329%Not Available
Bone marrow failure01.03.03.0050.000461%
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.0220.001384%Not Available
Oral disorder07.05.01.0050.000395%Not Available
Cholestatic liver injury09.01.07.0160.000527%Not Available
Hypertransaminasaemia09.01.02.0050.000461%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.001252%
Acute kidney injury20.01.03.0160.007908%
Immune-mediated necrotising myopathy15.05.05.008; 10.04.05.0060.000198%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001318%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.055552%Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000052%Not Available
Pneumocystis jirovecii infection11.03.07.0040.000132%Not Available
Autoimmune haemolytic anaemia01.06.01.004; 10.04.01.0050.000329%Not Available
Candida infection11.03.03.0210.000132%
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.000461%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000533%
Liver function test increased13.03.01.044--Not Available
Blood blister23.03.01.028; 12.01.06.0130.000120%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.001647%Not Available
Lymphocytopenia neonatal18.04.03.004; 01.02.02.0040.000395%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.000132%Not Available
Palmoplantar keratoderma23.01.01.0070.000132%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages